OP 801 - Orpheris
Alternative Names: 18F OP 801; OP-801; PET DendrimerLatest Information Update: 28 Jan 2025
At a glance
- Originator Ashvattha Therapeutics
- Developer Ashvattha Therapeutics; Orpheris
- Class Dendrimers; Diagnostic agents; Imaging agents
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Alzheimer's disease; Amyotrophic lateral sclerosis; Multiple sclerosis; Parkinson's disease
- No development reported Neurological disorders
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for preclinical development in Neurological-disorders(Diagnosis) in USA
- 10 Jun 2024 Pharmacodynamics data from a preclinical study in Multiple sclerosis released by Ashvattha Therapeutics
- 01 Feb 2024 Phase-I/II clinical trials in Alzheimer's disease (Diagnosis) in USA (IV) (NCT05395624)